SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Array Biopharma, Inc. - ARRY

NEW YORK, Nov. 21, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Array Biopharma, Inc. ("Array Biopharma" or the "Company") (NASDAQ: ARRY).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Array and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On March 19, 2017, Array issued a press release announcing the withdrawal of the New Drug Application ("NDA") for the Company's cancer drug binimetinib, stating that "based on feedback from the [U.S. Food and Drug Administration], Array concluded that the clinical benefit demonstrated in [a recent Phase 3 clinical trial] would not be found sufficient to support approval" of the NDA. 

On this news, Array's share price fell $1.43, or 13.5%, over the following two trading days, to close at $9.13 on March 21, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-array-biopharma-inc---arry-300560566.html

SOURCE Pomerantz LLP